Related Experiment Video
Updated: Aug 16, 2026
Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease
Published on: August 26, 2017
Microvascular involvement in cardiac pathology
Insights
Microvascular abnormalities play a key role in heart disease progression and outcomes. Understanding these changes in conditions like myocarditis and ischemic heart disease can help minimize heart muscle loss.
Area of Science:
- Cardiovascular Research
- Pathophysiology
- Medical Science
Background:
- Microvascular abnormalities are integral to the development and progression of various heart conditions.
- These changes can be a primary cause or a consequence of heart disease, impacting conditions like viral myocarditis and Chagas' disease.
- Focal microvascular issues are observed early in some cardiomyopathies and later in most myocarditis cases.
Purpose of the Study:
- To elucidate the role of microvascular abnormalities in the pathogenesis and progression of heart diseases.
- To understand the mechanisms behind microvascular dysfunction in conditions such as hypertension, myocarditis, and ischemic heart disease.
- To identify potential therapeutic targets for minimizing myocyte loss by modulating angiogenesis and leukocyte activity.
Main Methods:
- Review and synthesis of existing literature on microvascular changes in cardiac diseases.
- Analysis of pathological mechanisms including arteriolar wall thickening, impaired angiogenesis, and microvascular stunning.
- Examination of inflammatory responses and cellular events contributing to microvascular dysfunction.
Main Results:
- Chronic hypertension leads to arteriolar wall thickening, impairing coronary hemodynamics and reducing coronary reserve.
- Ischemic myocyte injury can result in the no-reflow phenomenon and reduced functional capillaries due to microvascular stunning.
- Mechanisms of microvascular stunning include reperfusion injury, leukocyte activation, and impaired vasodilation.
- Microvascular changes often represent a common inflammatory pathway in myocarditis, cardiomyopathy, and ischemic heart disease.
Conclusions:
- Microvascular abnormalities are a critical factor in the pathophysiology of diverse heart diseases.
- Interventions targeting angiogenesis and leukocyte activity hold promise for preserving cardiac function and minimizing myocyte loss.
- Understanding these microvascular mechanisms is essential for developing effective treatments for heart failure and ischemic heart disease.
Abstract:
Abnormalities of the microvasculature are centrally involved in the pathogenesis of some forms of heart disease, but in others are consequences of it. Microvascular abnormalities may contribute to the progression of viral myocarditis and Chagas' disease. Focal abnormalities may occur early in some cardiomyopathies and do occur later in most types of myocarditis. The thickening of arteriolar walls in chronic hypertension is likely to contribute significantly to the impairment of coronary haemodynamics associated with adaptive ventricular hypertrophy and the consequent diminution of coronary reserve, increasing diffusion distances and failure of angiogenesis to compensate. However, the resulting myocyte necrosis stimulates inflammatory angiogenesis. When ischemic myocyte injury becomes irreversible there is a concomitant loss of capacity for reperfusion, the no-reflow phenomenon. Less severe temporary ischemia reduces the proportion of functional capillaries. Multiple mechanisms are involved in this microvascular stunning, including: reperfusion injury; leukocyte activation; adhesion and accumulation; and impaired endothelium-dependent vasodilation. Many of the microvascular changes are those of the inflammatory response to cell death and form part of a final common pathway in myocarditis, cardiomyopathy, cardiac hypertrophy and failure, and ischemic heart disease. Stimulation of angiogenesis prior to myocyte necrosis in hypertrophy and control of leukocyte activity in ischemic heart disease could minimize myocyte loss.
Related Concept Videos
01:21Myocarditis I: Introduction
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy